Doxazosin
Cardura, Doxazosin (doxazosin) is a small molecule pharmaceutical. Doxazosin was first approved as Cardura on 1990-11-02. It is used to treat hypertension, prostatic hyperplasia, and urinary retention in the USA. The pharmaceutical is active against alpha-1A adrenergic receptor, alpha-1B adrenergic receptor, and alpha-1D adrenergic receptor.
Download report
Favorite
Events Timeline
Commercial
Clinical
Drug
Target
Variants
Financial
Trends
Safety
Events Timeline
5D
1M
3M
6M
YTD
1Y
2Y
5Y
Max
Events
FDA approval date
EMA approval date
Patent expiration date
Study first post date
Last update post date
Start date
Primary completion date
Completion date
Results first post date
Mock data
Subscribe for the real data
Subscribe for the real data
Commercial
Therapeutic Areas
Therapeutic Area | MeSH |
|---|---|
| urogenital diseases | D000091642 |
| cardiovascular diseases | D002318 |
Trade Name
FDA
EMA
Cardura (generic drugs available since 2000-10-18)
Drug Products
FDA
EMA
Labels
FDA
EMA
Brand Name | Status | Last Update |
|---|---|---|
| cardura | New Drug Application | 2023-05-15 |
| cardura xl | New Drug Application | 2010-03-24 |
| doxazosin | ANDA | 2024-01-22 |
| doxazosin doxazosin mesylate | NDA authorized generic | 2022-01-20 |
| doxazosin mesylate | ANDA | 2024-01-23 |
| ibuprofen | ANDA | 2022-01-27 |
Indications
FDA
EMA
Indication | Ontology | MeSH | ICD-10 |
|---|---|---|---|
| hypertension | EFO_0000537 | D006973 | I10 |
| prostatic hyperplasia | EFO_0000284 | D011470 | N40 |
| urinary retention | HP_0000016 | D016055 | R33 |
Agency Specific
FDA
EMA
No data
Patent Expiration
No data
ATC Codes
C: Cardiovascular system drugs
— C02: Antihypertensives
— C02C: Antiadrenergic agents, peripherally acting
— C02CA: Alpha-adrenoreceptor antagonists, peripherally acting
— C02CA04: Doxazosin
G: Genito urinary system and sex hormones
— G04: Urologicals
— G04C: Drugs used in benign prostatic hypertrophy
— G04CA: Alpha-adrenoreceptor antagonists, benign prostatic hypertrophy
— G04CA55: Doxazosin and finasteride
HCPCS
No data
Clinical
Clinical Trials
73 clinical trials
View more details
Mock data
Subscribe for the real data
Subscribe for the real data
Indications Phases 4
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Hypertension | D006973 | EFO_0000537 | I10 | 1 | 2 | 2 | 8 | 9 | 21 |
| Prostatic hyperplasia | D011470 | EFO_0000284 | N40 | — | 2 | 1 | 2 | 10 | 15 |
| Post-traumatic stress disorders | D013313 | EFO_0001358 | F43.1 | 1 | 3 | — | 1 | — | 5 |
| Cardiovascular diseases | D002318 | HP_0001626 | — | — | 1 | 1 | 1 | 1 | 4 |
| Pheochromocytoma | D010673 | — | — | — | — | 1 | 1 | 1 | 3 |
| Stroke | D020521 | EFO_0000712 | I63.9 | — | — | — | 1 | 1 | 2 |
| Essential hypertension | D000075222 | — | I10 | — | — | — | 2 | — | 2 |
| Diabetic nephropathies | D003928 | EFO_0000401 | — | — | — | 1 | 1 | — | 2 |
| Diabetes mellitus | D003920 | HP_0000819 | E08-E13 | — | — | 1 | 1 | — | 2 |
| Chronic renal insufficiency | D051436 | — | N18 | — | — | — | 1 | — | 1 |
Show 5 more
Indications Phases 3
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Coronary disease | D003327 | — | — | — | — | 1 | — | 2 | 3 |
| Heart diseases | D006331 | EFO_0003777 | I51.9 | — | 1 | 1 | — | 1 | 3 |
| Myocardial infarction | D009203 | EFO_0000612 | I21 | — | — | 1 | — | 1 | 2 |
| Kidney calculi | D007669 | EFO_0004253 | N20 | — | — | 1 | — | 1 | 2 |
| Heart failure | D006333 | HP_0001635 | I50 | — | — | 1 | — | — | 1 |
| Hypercholesterolemia | D006937 | HP_0003124 | — | — | — | 1 | — | — | 1 |
| Myocardial ischemia | D017202 | EFO_1001375 | I20-I25 | — | — | 1 | — | — | 1 |
| Paraganglioma | D010235 | — | — | — | — | 1 | — | — | 1 |
Indications Phases 2
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Cocaine-related disorders | D019970 | — | F14 | 4 | 3 | — | — | — | 6 |
| Alcoholism | D000437 | EFO_0003829 | F10.1 | 1 | 4 | — | — | — | 5 |
| Opioid-related disorders | D009293 | EFO_0005611 | F11 | — | 1 | — | — | — | 1 |
| Vascular diseases | D014652 | EFO_0004264 | I77 | — | 1 | — | — | — | 1 |
| Smoking | D012907 | EFO_0004318 | — | — | 1 | — | — | — | 1 |
| Anxiety | D001007 | EFO_0005230 | F41.1 | — | 1 | — | — | — | 1 |
Indications Phases 1
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Substance-related disorders | D019966 | EFO_0003890 | F13 | 3 | — | — | — | — | 3 |
| Erectile dysfunction | D007172 | EFO_0004234 | F52.21 | 1 | — | — | — | 1 | 2 |
| Healthy volunteers/patients | — | — | — | 1 | — | — | — | — | 1 |
| Amphetamine-related disorders | D019969 | EFO_0004701 | F15 | 1 | — | — | — | — | 1 |
| Mood disorders | D019964 | EFO_0004247 | F30-F39 | 1 | — | — | — | — | 1 |
Indications Without Phase
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Urolithiasis | D052878 | — | N20-N23 | — | — | — | — | 2 | 2 |
| Covid-19 | D000086382 | — | U07.1 | — | — | — | — | 1 | 1 |
| Microvascular angina | D017566 | — | — | — | — | — | — | 1 | 1 |
| Urinary retention | D016055 | HP_0000016 | R33 | — | — | — | — | 1 | 1 |
| Hyperaldosteronism | D006929 | HP_0011736 | E26 | — | — | — | — | 1 | 1 |
Epidemiology
Epidemiological information for investigational and approved indications
View more details
Drug
General
| Drug common name | Doxazosin |
| INN | doxazosin |
| Description | Doxazosin is a member of the class of quinazolines that is quinazoline substituted by an amino group at position 4, methoxy groups at positions 6 and 7 and a piperazin-1-yl group at position 2 which in turn is substituted by a 2,3-dihydro-1,4-benzodioxin-2-ylcarbonyl group at position 4. An antihypertensive agent, it is used in the treatment of high blood pressure. It has a role as an antihypertensive agent, an alpha-adrenergic antagonist, an antineoplastic agent, a vasodilator agent and an antihyperplasia drug. It is a member of quinazolines, a N-acylpiperazine, a N-arylpiperazine, a benzodioxine, a monocarboxylic acid amide and an aromatic amine. |
| Classification | Small molecule |
| Drug class | antihypertensives (prazosin type) |
| Image (chem structure or protein) |  |
| Structure (InChI/SMILES or Protein Sequence) | COc1cc2nc(N3CCN(C(=O)C4COc5ccccc5O4)CC3)nc(N)c2cc1OC |
Identifiers
| PDB | — |
| CAS-ID | 74191-85-8 |
| RxCUI | — |
| ChEMBL ID | CHEMBL707 |
| ChEBI ID | 4708 |
| PubChem CID | 3157 |
| DrugBank | DB00590 |
| UNII ID | NW1291F1W8 (ChemIDplus, GSRS) |
Target
Agency Approved
ADRA1A
ADRA1A
ADRA1B
ADRA1B
ADRA1D
ADRA1D
Organism
Homo sapiens
Gene name
ADRA1A
Gene synonyms
ADRA1C
NCBI Gene ID
Protein name
alpha-1A adrenergic receptor
Protein synonyms
Alpha-1A adrenoceptor, Alpha-1A adrenoreceptor, Alpha-1C adrenergic receptor, Alpha-adrenergic receptor 1c, G protein coupled receptor
Uniprot ID
Mouse ortholog
Adra1a (11549)
alpha-1A adrenergic receptor (Q8BV77)
Alternate
No data
Variants
No data
Financial
Revenue by drug
$
€
£
₣
Cardura – Pfizer
Mock data
Subscribe for the real data
Subscribe for the real data
Mock data
Subscribe for the real data
Subscribe for the real data
Tabular view
Estimated US medical usage
Doxazosin
Total medical expenditures per year (USD, in millions)
Mock data
Subscribe for the real data
Subscribe for the real data
Number of persons purchased
Mock data
Subscribe for the real data
Subscribe for the real data
Number of purchases
Mock data
Subscribe for the real data
Subscribe for the real data
Refill frequency
Mock data
Subscribe for the real data
Subscribe for the real data
Price per prescription (USD)
Mock data
Subscribe for the real data
Subscribe for the real data
Tabular view
Trends
PubMed Central
Top Terms for Disease or Syndrome:
Mock data
Subscribe for the real data
Subscribe for the real data
Additional graphs summarizing 5,226 documents
View more details
Safety
Black-box Warning
Black-box warning for: Ibuprofen
Adverse Events
Top Adverse Reactions
Mock data
Subscribe for the real data
Subscribe for the real data
7,543 adverse events reported
View more details
© 2020-2024 Collaborative Drug Discovery Inc. (CDD) | Terms of Use